Protocadherin 10 suppresses tumorigenesis and metastasis in colorectal cancer and its genetic loss predicts adverse prognosis

International Journal of Cancer

Volumn 135, Issue 11, 2014, Pages 2593-2603

  Jao, Tzu Ming ^a   Tsai, Ming Hong ^b,c   Lio, Hoi Yan ^a   Weng, Wei Ting ^a   Chen, Chun Chieh ^a   Tzeng, Sheng Tai ^a   Chang, Chia Yun ^a   Lai, Yen Chun ^a   Yen, Sou Jhy ^b   Yu, Sung Liang ^a,d   Yang, Ya Chien ^a,d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CARDINAL TIEN HOSPITAL   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Colorectal cancer; Liver metastasis; Loss of heterozygosity; PCDH10; Prognostic marker

Indexed keywords

CADHERIN; PROTOCADHERIN 10; UNCLASSIFIED DRUG; MESSENGER RNA; PCDH10 PROTEIN, HUMAN;

ADULT; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DISTANT METASTASIS; GENE DELETION; GENE EXPRESSION REGULATION; GENE LOSS; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PCDH10 GENE; PREDICTION; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR INVASION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; CANCER STAGING; CELL ADHESION; CELL MOTION; CELL TRANSFORMATION; COLORECTAL NEOPLASMS; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE SILENCING; GENETICS; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; SECONDARY; SURVIVAL RATE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CADHERINS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LOSS OF HETEROZYGOSITY; MALE; MICE; MICE, SCID; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 84921651442     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28899     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006;244:254-9.
3. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-87.
4. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
5. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009;361:2449-60.
6. van Engeland M, Derks S, Smits KM, et al. Colorectal cancer epigenetics: complex simplicity. J Clin Oncol 2011;29:1382-91.
7. Bendardaf R, Lamlum H, Pyrhonen S. Prognostic and predictive molecular markers in colorectal carcinoma. Anticancer Res 2004;24:2519-30.
8. Duffy MJ, O'Donovan N, Crown J. Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev 2011;37:151-9.
9. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008;135:1079-99.
10. Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009;9:489-99.
11. Harrison S, Benziger H. The molecular biology of colorectal carcinoma and its implications: a review. Surgeon 2011;9:200-10.
12. Arribas R, Ribas M, Risques RA, et al. Prospective assessment of allelic losses at 4p14-16 in colorectal cancer: two mutational patterns and a locus associated with poorer survival. Clin Cancer Res 1999;5:3454-9.
13. Shivapurkar N, Maitra A, Milchgrub S, et al. Deletions of chromosome 4 occur early during the pathogenesis of colorectal carcinoma. Hum Pathol 2001;32:169-77.
14. Jones AM, Thirlwell C, Howarth KM, et al. Analysis of copy number changes suggests chromosomal instability in a minority of large colorectal adenomas. J Pathol 2007;213:249-56.
15. Singh RK, Indra D, Mitra S, et al. Deletions in chromosome 4 differentially associated with the development of cervical cancer: evidence of slit2 as a candidate tumor suppressor gene. Hum Genet 2007;122:71-81.
16. Wrage M, Ruosaari S, Eijk PP, et al. Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res 2009;15:1566-74.
17. Arai Y, Honda S, Haruta M, et al. Genome-wide analysis of allelic imbalances reveals 4q deletions as a poor prognostic factor and MDM4 amplification at 1q32.1 in hepatoblastoma. Genes Chromosomes Cancer 2010;49:596-609.
18. Tzeng ST, Tsai MH, Chen CL, et al. NDST4 is a novel candidate tumor suppressor gene at chromosome 4q26 and its genetic loss predicts adverse prognosis in colorectal cancer. PLoS One 2013;8:e67040.
19. Hirano S, Yan Q, Suzuki ST. Expression of a novel protocadherin, OL-protocadherin, in a subset of functional systems of the developing mouse brain. J Neurosci 1999;19:995-1005.
20. Redies C, Vanhalst K, Roy F. delta-Protocadherins: unique structures and functions. Cell Mol Life Sci 2005;62:2840-52.
21. Uemura M, Nakao S, Suzuki ST, et al. OL-Protocadherin is essential for growth of striatal axons and thalamocortical projections. Nat Neurosci 2007;10:1151-9.
22. Nakao S, Platek A, Hirano S, et al. Contactdependent promotion of cell migration by the OL-protocadherin-Nap1 interaction. J Cell Biol 2008;182:395-410.
23. Morrow EM, Yoo SY, Flavell SW, et al. Identifying autism loci and genes by tracing recent shared ancestry. Science 2008;321:218-23.
24. Ying J, Li H, Seng TJ, et al. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene 2006;25:1070-80.
25. Ying J, Gao Z, Li H, et al. Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. Br J Haematol 2007;136:829-32.
26. Yu J, Cheng YY, Tao Q, et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 2009;136:640-51 e1.
27. Narayan G, Scotto L, Neelakantan V, et al. Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer. Genes Chromosomes Cancer 2009;48:983-92.
28. Li Z, Li W, Xie J, et al. Epigenetic inactivation of PCDH10 in human prostate cancer cell lines. Cell Biol Int 2011;35:671-6.
29. Bertrand KC, Mack SC, Northcott PA, et al. PCDH10 is a candidate tumour suppressor gene in medulloblastoma. Childs Nerv Syst 2011;27: 1243-9.
30. Tang X, Yin X, Xiang T, et al. Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer. Cancer Biomark 2012;12:11-19.
31. Zhong X, Zhu Y, Mao J, et al. Frequent epigenetic silencing of PCDH10 by methylation in human colorectal cancer. J Cancer Res Clin Oncol 2013;139:485-90.
32. Lin YL, Li ZG, Guan TY. The clinical significance of PCDH10 promoter methylation in patients with bladder transitional cell carcinoma. Urol Int 2013;90:219-24.
33. Tsai MH, Fang WH, Lin SW, et al. Mitochondrial genomic instability in colorectal cancer: no correlation to nuclear microsatellite instability and allelic deletion of hMSH2, hMLH1, and p53 genes, but prediction of better survival for Dukes' stage C disease. Ann Surg Oncol 2009;16:2918-25.
34. Martins WS, Soares Lucas DC, de Souza Neves KF, et al. WebSat-a web software for microsatellite marker development. Bioinformation 2009;3: 282-3.
35. Tsai MH, Fang WH, Lin SH, et al. Mapping of genetic deletions on chromosome 3 in colorectal cancer: loss of 3p25-pter is associated with distant metastasis and poor survival. Ann Surg Oncol 2011;18:2662-70.
36. Tsai MH, Yang YC, Chen KH, et al. RER and LOH association with sporadic colorectal cancer in Taiwanese patients. Hepatogastroenterology 2002;49:672-7.
37. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25:402-8.
38. Hiraoka K, Kimura T, Logg CR, et al. Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. Cancer Res 2007;67:5345-53.
39. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-3.
40. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
41. Narayan G, Freddy AJ, Xie D, et al. Promoter methylation-mediated inactivation of PCDH10 in acute lymphoblastic leukemia contributes to chemotherapy resistance. Genes Chromosomes Cancer 2011;50:1043-53.
42. Narayan G, Xie D, Freddy AJ, et al. PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis. Genes Chromosomes Cancer 2013;52:1030-41.
43. Yu JS, Koujak S, Nagase S, et al. PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene 2008;27: 4657-65.
44. Perea J, Lomas M, Hidalgo M. Molecular basis of colorrectal cancer: towards an individualized management? Rev Esp Enferm Dig 2011;103:29-35.
45. Silva TD, Vidigal VM, Felipe AV, et al. DNA methylation as an epigenetic biomarker in colorectal cancer. Oncol Lett 2013;6:1687-92.
46. Danese E, Minicozzi AM, Benati M, et al. Epigenetic alteration: new insights moving from tissue to plasma-the example of PCDH10 promoter methylation in colorectal cancer. Br J Cancer 2013;109:807-13.
47. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:8681-6.
48. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008;27:6920-9.
49. Redies C, Hertel N, Hubner CA. Cadherins and neuropsychiatric disorders. Brain Res 2012;1470: 130-44.
50. Homayouni R, Rice DS, Curran T. Disabled-1 interacts with a novel developmentally regulated protocadherin. Biochem Biophys Res Commun 2001;289:539-47.